Sinopharm Tech Holdings Limited (Sinopharm Tech) filed its Monthly Return for the period ended 31 August 2026, confirming a stable share‐capital structure and continued compliance with Hong Kong’s 25% minimum public-float requirement.

Authorised and Issued Capital • Authorised share capital held steady at HKD 200.00 million, divided into 12.80 billion ordinary shares and 3.20 billion non-voting convertible preference shares (CPS), each with a par value of HKD 0.0125. • Issued ordinary shares remained unchanged at 633.69 million. No treasury shares were held or cancelled during the month. • Issued CPS also stayed flat at 1.48 billion. These securities, carrying a conversion price of HKD 0.10 per share, can be exchanged into ordinary shares on a one-for-one basis at any time up to November 2034, implying potential creation of up to 1.48 billion new ordinary shares upon full conversion.

Equity Incentives • Under the 2021 Share Option Scheme, 4.96 million options were outstanding at month-end. The exercise price, adjusted for past share consolidation, is HKD 1.00. No options were exercised in August, leaving the issued-share count unchanged. An additional 12.42 million shares may still be granted under this scheme.

Capital Reorganisation Context • The current capital structure reflects the November 2024 reorganisation, which subdivided each previously authorised but unissued HKD 0.3125 share into 25 shares of HKD 0.0125, while keeping total authorised capital at HKD 200.00 million. • The existing CPS position originated from the November 2024 completion of the IAM Loan and Creative Big Loan capitalisation agreements, which added 1.48 billion CPS to the register.

Regulatory Compliance • Sinopharm Tech confirmed that public float exceeded the mandated 25% threshold as at 31 August 2026. • The board affirmed full compliance with Hong Kong Listing Rules and all statutory filing and disclosure obligations.

Financial Impact With no new ordinary shares issued, no share buy-backs, and no CPS conversions in August, Sinopharm Tech’s share capital base and dilution metrics were unchanged. The company retains material potential dilution capacity through outstanding options (4.96 million shares) and unconverted CPS (1.48 billion shares), but no inflows or outflows of capital occurred during the month.